<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="3-part\PMC7074809\results\search\disease\results.xml">
  <result pre="of a safe and effective vaccine, in 2018, around 350,000" exact="measles" post="cases were reported worldwide, which resulted in an estimate"/>
  <result pre="estimate of 142,300 deaths from measles. Additionally, in 2017, global" exact="measles" post="cases spiked, causing the death of 110,000 people, mostly"/>
  <result pre="age of 5 years and immunocompromised adults. The increase in" exact="measles" post="incidence is caused by the ongoing reduction of vaccination"/>
  <result pre="scientific interest. For this reason, we reviewed the pathophysiology of" exact="measles" post="infection, focusing on mechanisms by which the virus spreads"/>
  <result pre="the lymphocytes from the airways through a &quot;trojan horse�? strategy," exact="measles" post="induces an immunosuppression status. H and F glycoproteins, both"/>
  <result pre="symptoms, diagnosis, prevention, and treatment completes and enriches the review." exact="measles" post="immunity viral–host interactions 1. Introduction Measles virus (MV) belongs"/>
  <result pre="acute highly contagious infection usually seen in children. Recovery from" exact="measles" post="is the rule but severe complications may develop in"/>
  <result pre="fusion (F) proteins. It is possible to differentiate between wildtype" exact="measles" post="virus and vaccine-type virus. The gene sequences for nucleoprotein"/>
  <result pre="nucleoprotein (N) and H are among the most variable of" exact="measles" post="and are among the most used to differentiate the"/>
  <result pre="and are among the most used to differentiate the various" exact="measles" post="genotypes [4]. MV owns six structural proteins (F, H,"/>
  <result pre="other paramyxoviruses, neuraminidase is not found on the envelope of" exact="measles" post="virus [5]. The major receptor for MV is the"/>
  <result pre="world and humans are the only natural host for wildtype" exact="measles" post="virus, but monkeys may also be infected [8]. Without"/>
  <result pre="also be infected [8]. Without a vaccine, the epidemics of" exact="measles" post="lasting 3 to 4 months could be predicted to"/>
  <result pre="predicted to occur every 2 to 5 years [9]. Annual" exact="measles" post="outbreaks typically occur in late winter and early spring"/>
  <result pre="public places, such as schools [1,9]. Countries in which the" exact="measles" post="vaccine is widely used have experienced a marked decrease"/>
  <result pre="vaccination policies, in populations that have received two doses of" exact="measles" post="vaccine, the age distribution of measles is shifted into"/>
  <result pre="received two doses of measles vaccine, the age distribution of" exact="measles" post="is shifted into adolescence and adulthood [12]. In addition"/>
  <result pre="change in the epidemic curve by age, the number of" exact="measles" post="outbreaks has increased in areas with reduced vaccination coverage"/>
  <result pre="regard, in Italy, in early January 2017, 2851 cases of" exact="measles" post="were reported: 73% with age &amp;gt;15 years and 27%"/>
  <result pre="to lymphocytes, initiating the infection [20]. 4.2. Replication Stage The" exact="measles" post="incubation phase is quite long, about 10 days before"/>
  <result pre="frequently observed in lymphoid tissues before the onset of a" exact="rash" post="[21]. After these first sites of replication, MV also"/>
  <result pre="known if it is dependent on the greater cytotoxicity of" exact="measles" post="against the lymphocytes or their greater susceptibility to the"/>
  <result pre="Transmission The contagiousness period is difficult to define, since the" exact="measles" post="RNA can be detected for long periods, even months,"/>
  <result pre="several hours in the air [26]. The incubation period of" exact="measles" post="is about 10–14 days, four days before rash onset"/>
  <result pre="period of measles is about 10–14 days, four days before" exact="rash" post="onset until four days after its appearance [25]. The"/>
  <result pre="has to be kept in mind that the contagiousness of" exact="measles" post="is among the highest among viruses and MV can"/>
  <result pre="is the birth rate [28]. In recent years, cases of" exact="measles" post="transmissibility have also been highlighted among vaccinated patients (even"/>
  <result pre="spots, which occur the day before the onset of the" exact="rash" post="and persist for 2 or 3 days. Koplik spots"/>
  <result pre="some cases, skin manifestations can also affect the palms. The" exact="rash" post="lasts 3–7 days, in some cases followed by a"/>
  <result pre="maculopapular rash, fever (≥38 °C), and either cough, coryza, or" exact="conjunctivitis" post="has a high sensitivity (75–90%) but a low positive"/>
  <result pre="but a low positive predictive value when the incidence of" exact="measles" post="is low, hence the need for serological confirmation [35]."/>
  <result pre="Transaminases elevation is a common finding, with two thirds of" exact="measles" post="patients experiencing it [36]. In the past, measles-associated hepatitis"/>
  <result pre="of measles patients experiencing it [36]. In the past, measles-associated" exact="hepatitis" post="was thought to be related to the severity of"/>
  <result pre="of the infection, but this has not been confirmed. Measles" exact="hepatitis" post="is more common in children than in adults, the"/>
  <result pre="or both. Pneumonia is the most common severe complication of" exact="measles" post="and accounts for most measles-associated deaths [39]. It can"/>
  <result pre="for most measles-associated deaths [39]. It can be caused by" exact="measles" post="alone or can be secondary to viral infection with"/>
  <result pre="adenovirus or HSV (some children have the clinical pattern of" exact="bronchiolitis" post="mediated by viruses), or secondary to a bacterial superinfection"/>
  <result pre="occur in otherwise normal adults and children. About 30% of" exact="pneumonia" post="cases are caused by bacteria, with the most often"/>
  <result pre="pneumomediastinum and mediastinal emphysema may develop [43]. Measles-associated episodes of" exact="myocarditis" post="have rarely been described. In the past, it was"/>
  <result pre="rarely been described. In the past, it was hypothesized that" exact="myocarditis" post="cases were associated with streptococcal superinfection, but this has"/>
  <result pre="intestinal tracts of most people affected with measles. Cases of" exact="appendicitis" post="have been reported before and during the rash. In"/>
  <result pre="during the rash. In these cases, giant cells typical of" exact="measles" post="were found in the intestinal epithelium [45]. In the"/>
  <result pre="the etiology of these cases is similar to that of" exact="diarrhea" post="in children not infected with measles [2]. Cases of"/>
  <result pre="similar to that of diarrhea in children not infected with" exact="measles" post="[2]. Cases of Noma associated with measles have also"/>
  <result pre="not infected with measles [2]. Cases of Noma associated with" exact="measles" post="have also been described in developing countries [46]. Febrile"/>
  <result pre="countries [46]. Febrile seizures occur in 0.1–2.3% of children with" exact="measles" post="in the United States and England [45], often without"/>
  <result pre="brain [47]. There are three rare but serious complications of" exact="measles" post="that can involve the central nervous system (CNS). Acute"/>
  <result pre="that can involve the central nervous system (CNS). Acute disseminated" exact="encephalomyelitis" post="(ADEM) is a demyelinating autoimmune disease often triggered by"/>
  <result pre="nervous system (CNS). Acute disseminated encephalomyelitis (ADEM) is a demyelinating" exact="autoimmune disease" post="often triggered by viral infections and occurring within days"/>
  <result pre="occurring within days to weeks in approximately 1 in 1000" exact="measles" post="cases. Measles inclusion body encephalitis (MIBE) is more common"/>
  <result pre="in approximately 1 in 1000 measles cases. Measles inclusion body" exact="encephalitis" post="(MIBE) is more common in hosts with immune system"/>
  <result pre="equal to a case rate of 1:609 for children with" exact="measles" post="under the year of life [49]. Based on the"/>
  <result pre="of life [49]. Based on the number of cases of" exact="measles" post="in children during 1989 to 1991, and the number"/>
  <result pre="years, it was estimated that the risk of SSPE after" exact="measles" post="is 1 per 11,000 cases, 10 times greater than"/>
  <result pre="revealed that these SSPE cases were caused by the wildtype" exact="measles" post="virus circulating during those years. It appears therefore that"/>
  <result pre="was originally estimated [50]. Patients with SSPE have unusually high" exact="measles" post="antibody titers in both serum and cerebrospinal fluid. The"/>
  <result pre="measles antibody titers in both serum and cerebrospinal fluid. The" exact="measles" post="virus is thought to spread to the brain during"/>
  <result pre="is thought to spread to the brain during the acute" exact="rash" post="when other endothelial cells are also infected. A trans-synaptic"/>
  <result pre="the virus has also been hypothesized recently. Contrary to the" exact="measles" post="virus infection of non-neuronal cells, however, in this district,"/>
  <result pre="been described how in the presence of some antibodies to" exact="measles" post="it is possible to modify the expression pattern of"/>
  <result pre="Special Groups A particular situation to remember is associated with" exact="measles" post="infection in patients partially vaccinated with 1960s inactivated (killed)"/>
  <result pre="measles infection in patients partially vaccinated with 1960s inactivated (killed)" exact="measles" post="vaccine (KMV) that sensitized the patient to measles virus"/>
  <result pre="inactivated (killed) measles vaccine (KMV) that sensitized the patient to" exact="measles" post="virus antigens without providing protection. Subsequent measles virus infection"/>
  <result pre="the patient to measles virus antigens without providing protection. Subsequent" exact="measles" post="virus infection leads to signs of hypersensitivity polyserositis and"/>
  <result pre="providing protection. Subsequent measles virus infection leads to signs of" exact="hypersensitivity" post="polyserositis and these developed into high fever, a rash"/>
  <result pre="of hypersensitivity polyserositis and these developed into high fever, a" exact="rash" post="that was more prominent at the extremities with petechiae"/>
  <result pre="was more prominent at the extremities with petechiae and frequent" exact="pneumonia" post="[2]. The form most often found in immunosuppressed, in"/>
  <result pre="contrast, is the one with pulmonary involvement, with or without" exact="rash" post="[1,3]. It was noted that in cases of malnutrition,"/>
  <result pre="gamma interferon (IFN-γ) and interleukin-2 (IL-2), is present during the" exact="measles" post="prodrome [62], whereas measles convalescence is characterized by elevations"/>
  <result pre="interleukin-2 (IL-2), is present during the measles prodrome [62], whereas" exact="measles" post="convalescence is characterized by elevations in Th2 cytokines, such"/>
  <result pre="centers, including thyme, sites of the initial spread of the" exact="measles" post="virus [63]. MV infection suppresses T-lymphocyte proliferation in response"/>
  <result pre="of the immune system alike. The syncytia induced by the" exact="measles" post="virus expressing the viral glycoproteins HA and F on"/>
  <result pre="virus has been reported: The incidence of malformations observed in" exact="measles" post="during pregnancy is comparable to that found in the"/>
  <result pre="vaccine must be administered before pregnancy [74]. 9. Diagnosis Classic" exact="measles" post="with cough, coryza, conjunctivitis, Koplik spots, and a maculopapular"/>
  <result pre="measles with cough, coryza, conjunctivitis, Koplik spots, and a maculopapular" exact="rash" post="that starts on the face can more easily target"/>
  <result pre="that starts on the face can more easily target the" exact="measles" post="hypothesis. Anyway, a laboratory confirmation is often useful when"/>
  <result pre="be diagnosed in the laboratory by viral isolation, identification of" exact="measles" post="antigen, or RNA in infected tissues (and nucleotide sequencing"/>
  <result pre="nasal exudates or from urinary sediment for the presence of" exact="measles" post="antigens may be useful for rapid diagnosis of measles."/>
  <result pre="Still remaining in the context of complications, the diagnosis of" exact="acute disseminated encephalomyelitis" post="is instead commonly made by the typical clinical picture."/>
  <result pre="in the context of complications, the diagnosis of acute disseminated" exact="encephalomyelitis" post="is instead commonly made by the typical clinical picture."/>
  <result pre="raised protein levels both greater than those typically found in" exact="multiple sclerosis." post="The cerebrospinal fluid oligoclonal band presence is less common"/>
  <result pre="The cerebrospinal fluid oligoclonal band presence is less common in" exact="acute disseminated encephalomyelitis" post="than in multiple sclerosis. Computed tomography images may be"/>
  <result pre="fluid oligoclonal band presence is less common in acute disseminated" exact="encephalomyelitis" post="than in multiple sclerosis. Computed tomography images may be"/>
  <result pre="presence is less common in acute disseminated encephalomyelitis than in" exact="multiple sclerosis." post="Computed tomography images may be of little significance while"/>
  <result pre="very characteristic) [77]. 10. Vaccine There are various types of" exact="measles" post="vaccines, the monocomponent is used in most African countries"/>
  <result pre="and in others, including Russia [78]. The combined mumps, measles," exact="rubella" post="(MMR) vaccine is used instead in the rest of"/>
  <result pre="administered before the age of 15 months, the susceptibility to" exact="measles" post="infection is higher at up to 2–4 fold [82]."/>
  <result pre="in the entire population. Precisely, the required vaccination coverage against" exact="measles" post="ranges from 93% to 95% with two doses of"/>
  <result pre="measles ranges from 93% to 95% with two doses of" exact="measles" post="vaccine [27,84]. With regard to the different types of"/>
  <result pre="of adaptive immunity are unclear [85]. Anyhow, the currently accepted" exact="measles" post="protection correlates to a titer of neutralizing antibodies specific"/>
  <result pre="[90]. Adverse Effects of Vaccination The adverse effects of the" exact="measles" post="vaccine are extremely infrequent and in most cases with"/>
  <result pre="Table 1 compares the incidence of the main complications of" exact="measles" post="infection and that of side effects after the measles"/>
  <result pre="of measles infection and that of side effects after the" exact="measles" post="vaccine [91]. 11. Therapy There is no current standardized"/>
  <result pre="that of the administration of immunoglobulins, especially those specific for" exact="measles" post="[94]. Other clinical evidence would support the use of"/>
  <result pre="discussed, whose utility is described in some case reports of" exact="measles" post="pneumonia [95,96,97,98]. 12. Summary and Future Directions Various viruses"/>
  <result pre="whose utility is described in some case reports of measles" exact="pneumonia" post="[95,96,97,98]. 12. Summary and Future Directions Various viruses maintain"/>
  <result pre="a long period of preclinical viral shedding. In fact, the" exact="measles" post="virus in the early stages of infection, through interactions"/>
  <result pre="be shaded, meaning that it does not necessarily include the" exact="rash" post="and other pathognomonic elements; therefore, a hypothesis and clinical"/>
  <result pre="extremely effective for reducing or eliminating the circulation of the" exact="measles" post="virus is the vaccination. It should be remembered that"/>
  <result pre="that the vaccine administered in two doses confers immunity to" exact="measles" post="to approximately 97% of the population. The remaining 3%"/>
  <result pre="Lancet Journal (later withdrawn) in which correlations between vaccines and" exact="autism" post="were highlighted, and anti-vaccine movements for alleged safety issues"/>
  <result pre="2.PerryR.T.HalseyN.A.The clinical significance of measles: A reviewJ. Infect. Dis.2004189S4S1615106083 3.KaplanL.J.DaumR.S.SmaronM.McCarthyC.A.Severe" exact="measles" post="in immunocompromised patientsJAMA19922671237124110.1001/jama.1992.034800900850321538561 4.RotaP.A.LiffickS.L.RotaJ.S.KatzR.S.ReddS.PapaniaM.BelliniW.J.Molecular epidemiology of measles viruses in"/>
  <result pre="Infect. Dis.2004189S4S1615106083 3.KaplanL.J.DaumR.S.SmaronM.McCarthyC.A.Severe measles in immunocompromised patientsJAMA19922671237124110.1001/jama.1992.034800900850321538561 4.RotaP.A.LiffickS.L.RotaJ.S.KatzR.S.ReddS.PapaniaM.BelliniW.J.Molecular epidemiology of" exact="measles" post="viruses in the United States, 1997–2001Emerg. Infect. Dis.2002890290810.3201/eid0809.02020612194764 5.El"/>
  <result pre="infectious particle productionViruses201463019305410.3390/v608301925105277 6.TatsuoH.OnoN.TanakaK.YanagiY.Slam (cdw150) is a cellular receptor for" exact="measles" post="virusNature200040689389710.1038/3502257910972291 7.MuhlebachM.D.MateoM.SinnP.L.PruferS.UhligK.M.LeonardV.H.NavaratnarajahC.K.FrenzkeM.WongX.X.SawatskyB.et al.Adherens junction protein nectin-4 is the epithelial"/>
  <result pre="7.MuhlebachM.D.MateoM.SinnP.L.PruferS.UhligK.M.LeonardV.H.NavaratnarajahC.K.FrenzkeM.WongX.X.SawatskyB.et al.Adherens junction protein nectin-4 is the epithelial receptor for" exact="measles" post="virusNature201148053053310.1038/nature1063922048310 8.KempeC.H.FulginitiV.A.The pathogenesis of measles virus infectionArch. Gesamte Virusforsch.19651610312810.1007/BF0125379814322852"/>
  <result pre="is the epithelial receptor for measles virusNature201148053053310.1038/nature1063922048310 8.KempeC.H.FulginitiV.A.The pathogenesis of" exact="measles" post="virus infectionArch. Gesamte Virusforsch.19651610312810.1007/BF0125379814322852 9.FineP.E.ClarksonJ.A.Measles in england and wales—I:"/>
  <result pre="J. Epidemiol.19821151410.1093/ije/11.1.57085179 10.ClementsC.J.StrassburgM.CuttsF.T.TorelC.The epidemiology of measlesWorld Health Stat. Q.1992452852911462663 11.WallingaJ.HeijneJ.C.KretzschmarM.A" exact="measles" post="epidemic threshold in a highly vaccinated populationPLoS Med.20052e31610.1371/journal.pmed.002031616218769 12.SugermanD.E.BarskeyA.E.DeleaM.G.Ortega-SanchezI.R.BiD.RalstonK.J.RotaP.A.Waters-MontijoK.LebaronC.W.Measles"/>
  <result pre="VriesR.D.LemonK.LudlowM.McQuaidS.YukselS.van AmerongenG.RennickL.J.RimaB.K.OsterhausA.D.de SwartR.L.et al.In vivo tropism of attenuated and pathogenic" exact="measles" post="virus expressing green fluorescent protein in macaquesJ. Virol.2010844714472410.1128/JVI.02633-0920181691 15.Von"/>
  <result pre="marker pvrl4 (nectin 4) is an epithelial cell receptor for" exact="measles" post="virusPLoS Pathog.20117e100224010.1371/journal.ppat.100224021901103 18.AndresO.ObojesK.KimK.S.ter MeulenV.Schneider-SchauliesJ.Cd46- and cd150-independent endothelial cell infection"/>
  <result pre="Pathog.20117e100224010.1371/journal.ppat.100224021901103 18.AndresO.ObojesK.KimK.S.ter MeulenV.Schneider-SchauliesJ.Cd46- and cd150-independent endothelial cell infection with wild-type" exact="measles" post="virusesJ. Gen. Virol.2003841189119710.1099/vir.0.18877-012692284 19.LemonK.de VriesR.D.MesmanA.W.McQuaidS.van AmerongenG.YukselS.LudlowM.RennickL.J.KuikenT.RimaB.K.et al.Early target cells"/>
  <result pre="virusesJ. Gen. Virol.2003841189119710.1099/vir.0.18877-012692284 19.LemonK.de VriesR.D.MesmanA.W.McQuaidS.van AmerongenG.YukselS.LudlowM.RennickL.J.KuikenT.RimaB.K.et al.Early target cells of" exact="measles" post="virus after aerosol infection of non-human primatesPLoS Pathog.20117e100126310.1371/journal.ppat.100126321304593 20.De"/>
  <result pre="WitteL.YanagiY.van AmerongenG.McQuaidS.YukselS.GeijtenbeekT.B.DuprexW.P.OsterhausA.D.Predominant infection of cd150+ lymphocytes and dendritic cells during" exact="measles" post="virus infection of macaquesPLoS Pathog.20073e17810.1371/journal.ppat.003017818020706 21.LaksonoB.M.de VriesR.D.McQuaidS.DuprexW.P.de SwartR.L.Measles virus"/>
  <result pre="21.LaksonoB.M.de VriesR.D.McQuaidS.DuprexW.P.de SwartR.L.Measles virus host invasion and pathogenesisViruses2016821010.3390/v808021027483301 22.LudlowM.RennickL.J.SarlangS.SkibinskiG.McQuaidS.MooreT.de SwartR.L.DuprexW.P.Wild-type" exact="measles" post="virus infection of primary epithelial cells occurs via the"/>
  <result pre="Gen. Virol.20109197197910.1099/vir.0.016428-019923259 23.De VriesR.D.YukselS.OsterhausA.D.de SwartR.L.Specific cd8(+) t-lymphocytes control dissemination of" exact="measles" post="virusEur. J. Immunol.20104038839510.1002/eji.20093994919950186 24.RiddellM.A.MossW.J.HauerD.MonzeM.GriffinD.E.Slow clearance of measles virus rna"/>
  <result pre="control dissemination of measles virusEur. J. Immunol.20104038839510.1002/eji.20093994919950186 24.RiddellM.A.MossW.J.HauerD.MonzeM.GriffinD.E.Slow clearance of" exact="measles" post="virus rna after acute infectionJ. Clin. Virol.20073931231710.1016/j.jcv.2007.05.00617625962 25.SartwellP.E.The incubation"/>
  <result pre="JongA.FraaijP.L.A.RuijsW.L.M.NieuwenhuijseD.F.van den HamH.J.KoopmansM.P.G.et al.Studies into the mechanism of measles-associated immune" exact="suppression" post="during a measles outbreak in the netherlandsNat. Commun.20189494410.1038/s41467-018-07515-030470742 27.MossW.J.StrebelP.Biological"/>
  <result pre="al.Studies into the mechanism of measles-associated immune suppression during a" exact="measles" post="outbreak in the netherlandsNat. Commun.20189494410.1038/s41467-018-07515-030470742 27.MossW.J.StrebelP.Biological feasibility of measles"/>
  <result pre="a measles outbreak in the netherlandsNat. Commun.20189494410.1038/s41467-018-07515-030470742 27.MossW.J.StrebelP.Biological feasibility of" exact="measles" post="eradicationJ. Infect. Dis.2011204S47S5310.1093/infdis/jir06521666201 28.FerrariM.J.GraisR.F.BhartiN.ConlanA.J.BjornstadO.N.WolfsonL.J.GuerinP.J.DjiboA.GrenfellB.T.The dynamics of measles in sub-saharan"/>
  <result pre="27.MossW.J.StrebelP.Biological feasibility of measles eradicationJ. Infect. Dis.2011204S47S5310.1093/infdis/jir06521666201 28.FerrariM.J.GraisR.F.BhartiN.ConlanA.J.BjornstadO.N.WolfsonL.J.GuerinP.J.DjiboA.GrenfellB.T.The dynamics of" exact="measles" post="in sub-saharan AfricaNature200845167968410.1038/nature0650918256664 29.PhadkeV.K.BednarczykR.A.SalmonD.A.OmerS.B.Association between vaccine refusal and vaccine-preventable"/>
  <result pre="and vaccine-preventable diseases in the United States: A review of" exact="measles" post="and pertussisJAMA20163151149115810.1001/jama.2016.135326978210 30.KoplikH.The diagnosis of the invasion of measles"/>
  <result pre="of measles and pertussisJAMA20163151149115810.1001/jama.2016.135326978210 30.KoplikH.The diagnosis of the invasion of" exact="measles" post="from a study of the exanthema as it appears"/>
  <result pre="it appears on the buccal mucous membraneArch. Pediatr.19627916216514458330 31.SuringaD.W.BankL.J.AckermanA.B.Role of" exact="measles" post="virus in skin lesions and koplik’s spotsN. Engl. J."/>
  <result pre="in the developing worldProc. R. Soc. Med.1974671112111510.1177/0035915774067011134438295 35.HutchinsS.S.PapaniaM.J.AmlerR.MaesE.F.GrabowskyM.BrombergK.GlasglowV.SpeedT.BelliniW.J.OrensteinW.A.Evaluation of the" exact="measles" post="clinical case definitionJ. Infect. Dis.2004189S153S15915106104 36.DinhA.FleuretV.HanslikT.Liver involvement in adults"/>
  <result pre="36.DinhA.FleuretV.HanslikT.Liver involvement in adults with measlesInt. J. Infect. Dis.201317e1243e124410.1016/j.ijid.2013.06.01423938044 37.MohiuddinS.A.AlMaslamaniM.HashimS.PanthalayinitharayilH.K.AlkaabiS.R.AbdulwahabA.DerbalaM.Measles" exact="hepatitis" post="in a vaccinated liver transplant recipient: Case report and"/>
  <result pre="report and review of literatureClin. Case Rep.2017586787010.1002/ccr3.78328588828 38.HusseyG.D.ClementsC.J.Clinical problems in" exact="measles" post="case managementAnn. Trop. Paediatr.19961630731710.1080/02724936.1996.117478438985528 39.QuiambaoB.P.GatchalianS.R.HalonenP.LuceroM.SombreroL.PaladinF.J.MeurmanO.MerinJ.RuutuP.Coinfection is common in measles-associated"/>
  <result pre="39.QuiambaoB.P.GatchalianS.R.HalonenP.LuceroM.SombreroL.PaladinF.J.MeurmanO.MerinJ.RuutuP.Coinfection is common in measles-associated pneumoniaPediatr. Infect. Dis. J.199817899310.1097/00006454-199802000-000029493801 40.GremillionD.H.CrawfordG.E.Measles" exact="pneumonia" post="in young adults. An analysis of 106 casesAm. J."/>
  <result pre="young adults. An analysis of 106 casesAm. J. Med.19817153954210.1016/0002-9343(81)90203-57282741 41.LoukidesS.PanagouP.KolokourisD.KalogeropoulosN.Bacterial" exact="pneumonia" post="as a suprainfection in young adults with measlesEur. Respir."/>
  <result pre="reviewScand. J. Infect. Dis.20013363263311525364 44.FinkelH.E.Measles myocarditisAm. Heart J.19646767968310.1016/0002-8703(64)90339-414156015 45.GreenbergB.L.SackR.B.Salazar-LindoE.BudgeE.GutierrezM.CamposM.VisbergA.Leon-BaruaR.YiA.MaurutiaD.et al.Measles-associated" exact="diarrhea" post="in hospitalized children in lima, Peru: Pathogenic agents and"/>
  <result pre="J.19642757810.1136/bmj.2.5401.7514147791 47.HanninenP.ArstilaP.LangH.SalmiA.PaneliusM.Involvement of the central nervous system in acute, uncomplicated" exact="measles" post="virus infectionJ. Clin. Microbiol.19801161061310.1128/JCM.11.6.610-613.19807430331 48.BitnunA.ShannonP.DurwardA.RotaP.A.BelliniW.J.GrahamC.WangE.Ford-JonesE.L.CoxP.BeckerL.et al.Measles inclusion-body encephalitis caused"/>
  <result pre="acute, uncomplicated measles virus infectionJ. Clin. Microbiol.19801161061310.1128/JCM.11.6.610-613.19807430331 48.BitnunA.ShannonP.DurwardA.RotaP.A.BelliniW.J.GrahamC.WangE.Ford-JonesE.L.CoxP.BeckerL.et al.Measles inclusion-body" exact="encephalitis" post="caused by the vaccine strain of measles virusClin. Infect."/>
  <result pre="48.BitnunA.ShannonP.DurwardA.RotaP.A.BelliniW.J.GrahamC.WangE.Ford-JonesE.L.CoxP.BeckerL.et al.Measles inclusion-body encephalitis caused by the vaccine strain of" exact="measles" post="virusClin. Infect. Dis.19992985586110.1086/52044910589903 49.WendorfK.A.WinterK.ZipprichJ.SchechterR.HackerJ.K.PreasC.CherryJ.D.GlaserC.HarrimanK.Subacute sclerosing panencephalitis: The devastating measles"/>
  <result pre="of measles virusClin. Infect. Dis.19992985586110.1086/52044910589903 49.WendorfK.A.WinterK.ZipprichJ.SchechterR.HackerJ.K.PreasC.CherryJ.D.GlaserC.HarrimanK.Subacute sclerosing panencephalitis: The devastating" exact="measles" post="complication that might be more common than previously estimatedClin."/>
  <result pre="panencephalitis: More cases of this fatal disease are prevented by" exact="measles" post="immunization than was previously recognizedJ. Infect. Dis.20051921686169310.1086/49716916235165 51.GargR.K.Subacute sclerosing"/>
  <result pre="previously recognizedJ. Infect. Dis.20051921686169310.1086/49716916235165 51.GargR.K.Subacute sclerosing panencephalitisPostgrad. Med. J.200278637010.1136/pmj.78.916.6311807185 52.BreitfeldV.HashidaY.ShermanF.E.OdagiriK.YunisE.J.Fatal" exact="measles" post="infection in children with leukemiaLab. Invest.1973282792914348408 53.FosterA.SommerA.Childhood blindness from"/>
  <result pre="and treatmentBull. World Health Organ.1986646196233492298 54.PermarS.R.GriffinD.E.LetvinN.L.Immune containment and consequences of" exact="measles" post="virus infection in healthy and immunocompromised individualsClin. Vaccine Immunol.20061343744310.1128/CVI.13.4.437-443.200616603610"/>
  <result pre="naturePediatrics19561810914913335330 56.ChenR.T.MarkowitzL.E.AlbrechtP.StewartJ.A.MofensonL.M.PrebludS.R.OrensteinW.A.Measles antibody: Reevaluation of protective titersJ. Infect. Dis.19901621036104210.1093/infdis/162.5.10362230231 57.PermarS.R.MossW.J.RyonJ.J.MonzeM.CuttsF.QuinnT.C.GriffinD.E.Prolonged" exact="measles" post="virus shedding in human immunodeficiency virus-infected children, detected by"/>
  <result pre="cytotoxic t lymphocytes identify a cluster of epitopes on the" exact="measles" post="virus fusion proteinJ. Virol.1993672276228410.1128/JVI.67.4.2276-2284.19937680390 60.MullerC.P.AmmerlaanW.FleckensteinB.KraussS.KalbacherH.SchneiderF.JungG.WiesmullerK.H.Activation of t cells by"/>
  <result pre="the ragged tail of mhc class ii-presented peptides of the" exact="measles" post="virus fusion proteinInt. Immunol.1996844545610.1093/intimm/8.4.4458671631 61.PetteM.LiebertU.G.GobelU.Grosse-WildeH.HartungH.P.ToykaK.V.Measles virus-directed responses of cd4+"/>
  <result pre="the t cell activation process inside the cellVirology199218728028910.1016/0042-6822(92)90316-H1736530 64.Sanchez-LanierM.GuerinP.McLarenL.C.BankhurstA.D.Measles virus-induced" exact="suppression" post="of lymphocyte proliferationCell. Immunol.198811636738110.1016/0008-8749(88)90238-92460251 65.BellA.F.BurnsJ.B.FujinamiR.S.Measles virus infection of human"/>
  <result pre="that offer protection from other pathogensScience201936659960610.1126/science.aay648531672891 70.MoroiK.SaitoS.KurataT.SataT.YanagidaM.Fetal death associated with" exact="measles" post="virus infection of the placentaAm. J. Obstet. Gynecol.19911641107110810.1016/0002-9378(91)90596-J2014835 71.KobayashiK.TajimaM.ToishiS.FujimoriK.SuzukiY.UdagawaH.Fetal"/>
  <result pre="the placentaAm. J. Obstet. Gynecol.19911641107110810.1016/0002-9378(91)90596-J2014835 71.KobayashiK.TajimaM.ToishiS.FujimoriK.SuzukiY.UdagawaH.Fetal growth restriction associated with" exact="measles" post="virus infection during pregnancyJ. Perinat. Med.200533676810.1515/JPM.2005.01115841617 72.SiegelM.Congenital malformations following"/>
  <result pre="mumps, and hepatitis. Results of a cohort studyJAMA19732261521152410.1001/jama.1973.032301300090034800931 73.Bar-OnS.OchshornY.HalutzO.AboudyY.ManyA.Detection of" exact="measles" post="virus by reverse-transcriptase polymerase chain reaction in a placentaJ."/>
  <result pre="Virol.201929e205810.1002/rmv.205831237061 77.BennettoL.ScoldingN.Inflammatory/post-infectious encephalomyelitisJ. Neurol. Neurosurg. Psychiatry200475i22i2810.1136/jnnp.2003.03425614978147 78.DemicheliV.RivettiA.DebaliniM.G.Di PietrantonjC.Vaccines for measles," exact="mumps" post="and rubella in childrenEvid.-Based Child Health A Cochrane Rev."/>
  <result pre="encephalomyelitisJ. Neurol. Neurosurg. Psychiatry200475i22i2810.1136/jnnp.2003.03425614978147 78.DemicheliV.RivettiA.DebaliniM.G.Di PietrantonjC.Vaccines for measles, mumps and" exact="rubella" post="in childrenEvid.-Based Child Health A Cochrane Rev. J.201382076223810.1002/ebch.1948 79.MaS.J.LiX.XiongY.Q.YaoA.L.ChenQ.Combination"/>
  <result pre="the mmr vaccineJ. Law Biosci.2016371872510.1093/jlb/lsw05728798865 82.De SerresG.BoulianneN.DefayF.BrousseauN.BenoitM.LacoursiereS.GuillemetteF.SotoJ.OuakkiM.WardB.J.et al.Higher risk of" exact="measles" post="when the first dose of a 2-dose schedule of"/>
  <result pre="measles when the first dose of a 2-dose schedule of" exact="measles" post="vaccine is given at 12–14 months versus 15 months"/>
  <result pre="Infect. Dis.20125539440210.1093/cid/cis43922543023 83.Nic LochlainnL.M.de GierB.van der MaasN.van BinnendijkR.StrebelP.M.GoodmanT.de MelkerH.E.MossW.J.HahneS.J.M.Effect of" exact="measles" post="vaccination in infants younger than 9 months on the"/>
  <result pre="younger than 9 months on the immune response to subsequent" exact="measles" post="vaccine doses: A systematic review and meta-analysisLancet Infect. Dis.2019191246125410.1016/S1473-3099(19)30396-231548081"/>
  <result pre="A systematic review and meta-analysisLancet Infect. Dis.2019191246125410.1016/S1473-3099(19)30396-231548081 84.GayN.J.The theory of" exact="measles" post="elimination: Implications for the design of elimination strategiesJ. Infect."/>
  <result pre="Immunol.2010171055106510.1128/CVI.00131-1020463105 87.HaralambievaI.H.OvsyannikovaI.G.O’ByrneM.PankratzV.S.JacobsonR.M.PolandG.A.A large observational study to concurrently assess persistence of" exact="measles" post="specific b-cell and t-cell immunity in individuals following two"/>
  <result pre="Immunol.2006674175010.1038/nri188616977339 90.HaralambievaI.H.OvsyannikovaI.G.PankratzV.S.KennedyR.B.JacobsonR.M.PolandG.A.The genetic basis for interindividual immune response variation to" exact="measles" post="vaccine: New understanding and new vaccine approachesExpert Rev. Vaccines201312577010.1586/erv.12.13423256739"/>
  <result pre="New understanding and new vaccine approachesExpert Rev. Vaccines201312577010.1586/erv.12.13423256739 91.BesterJ.C.Measles and" exact="measles" post="vaccination: A reviewJAMA Pediatr.20161701209121510.1001/jamapediatrics.2016.178727695849 92.ForniA.L.SchlugerN.W.RobertsR.B.Severe measles pneumonitis in adults:"/>
  <result pre="Rev. Vaccines201312577010.1586/erv.12.13423256739 91.BesterJ.C.Measles and measles vaccination: A reviewJAMA Pediatr.20161701209121510.1001/jamapediatrics.2016.178727695849 92.ForniA.L.SchlugerN.W.RobertsR.B.Severe" exact="measles" post="pneumonitis in adults: Evaluation of clinical characteristics and therapy"/>
  <result pre="characteristics and therapy with intravenous ribavirinClin. Infect. Dis.19941945446210.1093/clinids/19.3.4547811865 93.Ortac ErsoyE.TanrioverM.D.OcalS.OzisikL.InkayaC.TopeliA.Severe" exact="measles" post="pneumonia in adults with respiratory failure: Role of ribavirin"/>
  <result pre="and therapy with intravenous ribavirinClin. Infect. Dis.19941945446210.1093/clinids/19.3.4547811865 93.Ortac ErsoyE.TanrioverM.D.OcalS.OzisikL.InkayaC.TopeliA.Severe measles" exact="pneumonia" post="in adults with respiratory failure: Role of ribavirin and"/>
  <result pre="trialBr. Med. J. (Clin. Res. Ed.)198729429429610.1136/bmj.294.6567.294 96.D’SouzaR.M.D’SouzaR.Vitamin A for treating" exact="measles" post="in childrenCochrane Database Syst. Rev.20024CD001479 97.RuppM.E.SchwartzM.L.BechardD.E.Measles pneumonia. Treatment of"/>
  <result pre="A in a severe case of measlesMedicine201796e915410.1097/MD.000000000000915429390321 99.BeneckeO.DeYoungS.E.Anti-vaccine decision-making and" exact="measles" post="resurgence in the United StatesGlob. Pediatr. Health201962333794X1986294910.1177/2333794X19862949 100.ShelbyA.ErnstK.Story and"/>
  <result pre="cell, immunoglobuline and cytokine trends during the natural history of" exact="measles" post="infection. microorganisms-08-00276-t001_Table 1Table 1 Comparison between main side effects"/>
  <result pre="infection. microorganisms-08-00276-t001_Table 1Table 1 Comparison between main side effects of" exact="measles" post="vaccination and main complications of measles infection. Adapted from"/>
  <result pre="main side effects of measles vaccination and main complications of" exact="measles" post="infection. Adapted from Bester [91]. Measles Vaccination Measles Infection"/>
  <result pre="media 7% Rash 5% Pneumonia 5% Febrile seizures 0.3–0.8% Primary" exact="measles" post="encephalitis 0.1–0.3% Thrombocytopenia 0.003% Acute postinfectious encephalomyelitis 0.1% Anaphylaxis"/>
  <result pre="7% Rash 5% Pneumonia 5% Febrile seizures 0.3–0.8% Primary measles" exact="encephalitis" post="0.1–0.3% Thrombocytopenia 0.003% Acute postinfectious encephalomyelitis 0.1% Anaphylaxis 0.0001%"/>
  <result pre="seizures 0.3–0.8% Primary measles encephalitis 0.1–0.3% Thrombocytopenia 0.003% Acute postinfectious" exact="encephalomyelitis" post="0.1% Anaphylaxis 0.0001% Subacute sclerosing panencephalitis 0.01% Encephalitis 0.00002%"/>
 </snippets>
</snippetsTree>
